BMS 275183
Alternative Names: BMS-275183Latest Information Update: 27 May 2009
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Taxanes
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Non-small cell lung cancer; Solid tumours
Most Recent Events
- 27 May 2009 Discontinued - Phase-I for Solid tumours in Belgium (PO)
- 27 May 2009 Discontinued - Phase-I for Solid tumours in USA (PO)
- 27 May 2009 Discontinued - Phase-II for Non-small cell lung cancer in Belgium (PO)